Background Parenchymal-sparing pancreatic surgery is ideal for lesions such as small pancreatic neuroendocrine tumors (PanNET). However, precise localization of these small tumors at surgery can be difficult. The placement of fiducials under endoscopic ultrasound (EUS) guidance (EUS-F) has been used to direct stereotactic radiation therapy for pancreatic adenocarcinoma. This report describes two cases in which placement of fiducials was used to guide surgical resection. This study aimed to assess the feasibility, safety, and efficacy of using EUS-F for intraoperative localization of small PanNETs. Methods A retrospective study analyzed two consecutive patients with small PanNETs who underwent EUS-F followed by enucleation in a tertiary-care referral hospital. The following features were examined: technical success and complication rates of EUS-F, visibility of the fiducial at the time of surgery, and fiducial migration. Results In the study, EUS-F was performed for two female patients with a 7-mm and a 9-mm PanNET respectively in the uncinate process and neck of the pancreas. In both patients, EUS-F was feasible with two Visicoil fiducials (Core Oncology, Santa Barbara, CA, USA) placed either within or adjacent to the tumors using a 22-gauge Cook Echotip needle. At surgery, the fiducials were clearly visible on intraoperative ultrasound, and both the tumor and the fiducials were successfully enucleated in both cases. No complications were associated with EUS-F, and no evidence of pancreatitis was shown either clinically or on surgical pathology. This investigation had the limitations of a small single-center study. Conclusions For patients undergoing enucleation, EUS-F is technically feasible and safe and aids intraoperative localization of small PanNETs. 
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Abbreviations

PanNET
Pancreatic neuroendocrine tumor EUS Endoscopic ultrasound EUS-F Endoscopic ultrasound guided fiducial placement EUS-FNA Endoscopic ultrasound guided fine needle aspiration EUS-T EUS-guided tattooing Small pancreatic neuroendocrine tumors (PanNETs) are being detected with increasing frequency due to the increased use and improved quality of abdominal imaging
Electronic supplementary material The online version of this article (doi:10.1007/s00464-013-2975-7) contains supplementary material, which is available to authorized users. [1, 2] . Patients with these small tumors are ideal candidates for pancreatic-sparing procedures such as enucleation that allow for greater preservation of pancreatic tissue and function than more extensive procedures such as pancreaticoduodenectomy or distal pancreatectomy. However, these small lesions can be difficult to detect at the time of surgery. Fiducials ( Fig. 1 ) are implantable radiographic markers that have been used for many years to mark soft tissue in radiology. More recently, the placement of fiducials under endoscopic ultrasound (EUS) guidance (EUS-F) has been used to locate mediastinal and pancreatic cancers before stereotactic radiation therapy [3, 4] . We report on two consecutive patients with small PanNETs who underwent fiducial placement and subsequent successful enucleation. Corp., Montvale, NJ, USA). All procedures were performed with the patient under propofol-based monitored anesthesia. Doppler was used to confirm the absence of blood vessels interposed between the ultrasound probe and the tumor.
Methods
Patients
A 22-gauge FNA needle (Echotip; Cook Endoscopy, Winston-Salem, NC, USA) was back-loaded with a Visicoil fiducial (length, 10 mm; diameter, 0.35 mm) (Core Oncology, Santa Barbara, CA, USA) ( Fig. 1 ) using a sterile technique. The stylet was withdrawn 2-3 cm, and the needle tip was inserted into sterile bone wax, which sealed the needle tip to prevent unintended fiducial loss during needle insertion.
The FNA needle was inserted into the tumor under EUS guidance, and the fiducial was deployed by advancing the stylet ( Fig. 2B ; Video 1). The EUS needle was withdrawn, and the procedure was repeated to place a second fiducial. Intraveneous antibiotics were given (cefotetan 1 g or clindamycin 600 mg) before fiducial placement, followed by a 5-day course of oral ciprofloxacin (500 mg twice daily). Complications were assessed immediately in the endoscopy recovery area and then 48 h later by telephone.
Results
Two patients underwent EUS-F. The first patient was a 61-year-old woman with a 7.4-mm well-circumscribed hypoechoic lesion identified in the uncinate process on a previous EUS (Fig. 2 ). This lesion had not been identified on a prior pancreatic protocol computed tomography (CT) scan (Fig. 3A ). An EUS-FNA was performed, which confirmed a well-differentiated PanNET at cytologic evaluation.
Two Visicoil fiducials were placed at the time of the EUS. Laparotomy was performed 14 days later. The lesion was identified using intraoperative ultrasound, and enucleation was performed. On gross pathology, the two fiducials were visible. The pathology confirmed a welldifferentiated 7-mm PanNET with negative margins.
The second patient was a 50-year-old woman who presented with hypoglycemia. A 9-mm lesion in the neck of the pancreas was identified on CT (Fig. 3B ). An EUS-FNA was performed, which confirmed a well-differentiated PanNET at cytologic evaluation.
Two Visicoils fiducials were placed within the lesion under EUS guidance. Surgery was performed 11 days later. The fiducials, identified using intraoperative ultrasound, had an appearance very similar to that seen on EUS (Fig. 4B, C) . The lesion was enucleated. The fiducials were clearly visible within the tumor on macroscopic examination (Fig. 4D) , with the tumor pathologically confirmed as a well-differentiated insulinoma. The histology showed no evidence of acute pancreatitis in either case. In both cases, the fiducials were placed without any difficulties and without the need for fluoroscopy. Both patients were contacted within 48 h after their procedure, and neither reported any complications.
Discussion
The traditional surgical management of a patient with a Pan-NET is a pancreaticoduodenectomy for lesions in the uncinate or head, and distal pancreatectomy with or without splenic preservation for lesions in the body or tail [5] . However these operations are associated with a complication rate of 30-40 % and can result in exocrine and endocrine insufficiency [6] .
Parenchymal-sparing pancreatic surgery, such as central pancreatectomy or enucleation, has been proposed for patients with small, well-demarcated lesions. This approach is associated with a lower incidence of long-term endocrine and exocrine insufficiency than standard resections [7] . One of the challenges faced by surgeons is that PanNETs can be difficult to identify.
Intraoperative ultrasound has been used to locate pancreatic lesions, with reported success rates of 60-91 % [8] [9] [10] [11] [12] . However, several reports describe surgeons unable to identify small lesions, particularly when laparoscopic ultrasound probes were used [10, [13] [14] [15] [16] . The use of intraoperative ultrasound with manual palpation for the lesion has been shown to increase the detection rate [17] . However, this then commits the patient to an open procedure, which is associated with longer surgical times and hospital stays [18] .
This study highlighted the difficulty identifying these small lesions. The first case involved a 7-mm PanNET that Fig. 2 A A 7 -mm pancreatic neuroendocrine tumor (PanNET) in the uncinate process identified only with endoscopic ultrasound (EUS). B Insertion of the needle into the PanNET. The fiducial is deployed by advancing the stylet. C A magnified view demonstrating the fiducial, which appears as a hyperechoic lesion within the tumor (arrow) Fig. 3 Computed tomography (CT) images from patients 1 and 2. A In patient 1, a pancreatic protocol CT with threedimensional (3D) reconstruction showed no abnormality, and the lesion was identified only on endoscopic ultrasound (EUS) (Fig. 2) . B Patient 2, with the CT image demonstrating a 9-mm hypervascular lesion in the pancreas Surg Endosc (2013) 27:3921-3926 3923
could not be identified on a pancreatic protocol CT scan. This was similar to other studies, including a series from the Massachusetts General Hospital in which four cases detected by EUS were not found on CT or magnetic resonance imaging (MRI). In one of these cases, the neoplasm could not be detected by either intraoperative ultrasound or manual palpation [19] . The surgical team was concerned that this lesion would be very difficult to identify on intraoperative ultrasound, which could necessitate conversion to a pancreaticoduodenectomy rather than enucleation. This scenario, in which a small neuroendocrine tumor in the head or uncinate could not be identified and required subsequent conversion to a pancreaticoduodenectomy, has been reported previously [20] . We therefore proposed placing a fiducial. Fiducials are commonly placed in a pancreatic adenocarcinoma, with the reflective surface used to identify the precise location of the tumor, thus decreasing the radiation field [3] . Fiducials also reflect ultrasound waves, a feature that we hypothesized would allow them to be identified using intraoperative ultrasound.
Traditional fiducials are placed with a 19-gauge FNA needle, which can be challenging for head or uncinate lesions, with reports describing failure to place fiducials in these locations [21] . We therefore chose to use the Visicoil fiducial, which can be placed through a 22-gauge FNA needle.
In both reported cases, the fiducials were placed without difficulty. Although traditional fiducials are better visualized on CT for stereotactic radiotherapy [3] , we had no difficulties identifying the Visicoil fiducials on intraoperative ultrasound in either of the two reported cases. Further studies are required to determine the optimal fiducial type for visualization on intraoperative ultrasound.
As an alternative to the placement of fiducials, EUSguided tattooing (EUS-T) has been described previously as a tumor-marking technique in patients undergoing laparascopic resection [22] . With this technique, the needle is placed just proximal to the tumor, and the tattoo is injected as the needle is withdrawn, leaving a tattoo on the surface of the pancreas (Fig. 5) .
Clinicians have found EUS-T useful for lesions in which the tumor site is close to where the needle exits the pancreas (i.e., where the tattoo is placed) (Fig. 5A) . Uncinate lesions usually are reached by placing the echoendoscope in the duodenal bulb and inserting the FNA needle through the head of the pancreas and into the uncinate process. Uncinate lesions are not suitable for EUS-guided tattooing because the site of the tattoo would be adjacent to the duodenal bulb rather than adjacent to the tumor (Fig. 5B) .
Because the fiducial is placed either within or beside the lesion, EUS-F offers very accurate tumor localization (Fig. 5C ) compared with EUS-T, which identifies the area but not the tumor. This precise tumor localization may be helpful for small lesions in which enucleation rather than an extensive resection is planned. Findings have shown EUS-T to decrease operative times because it allows rapid identification of the lesion [16] . In both of the reported cases, the surgeons were able to identify the lesions rapidly through the reflection of the fiducial on intraoperative ultrasound. Further larger studies are required to determine whether the placement of fiducials not only aids identification but also decreases operative time.
Neither of the reported cases had complications after fiducial placement. Large studies involving patients with pancreatic cancer also have reported few complications associated with fiducial placement [4, 16] .
In conclusion, EUS-F placement is a feasible and safe technique that can be used to mark a tumor site and guide surgical enucleation. This new application of interventional EUS may be considered for patients with small tumors in whom parenchymal-sparing resection is appropriate. A View showing how tattooing is used to mark the site of a lesion in the tail. The needle is inserted just in front of the lesion, and the gastrointestinal (GI) spot tattoo is injected as the needle is withdrawn leaving a tattoo (arrow). The tattoo then is visible on the surface of the pancreas. B View demonstrating how tattooing cannot be used to locate lesions in the uncinate process because the tattoo is visible only where the needle leaves the pancreas (arrow), which is distant from the actual location of the tumor (arrowhead). C View demonstrating placement of a fiducial. The fiducial is placed within or beside the tumor (arrowhead). The fiducial then can be identified easily using intraoperative ultrasound. (Copyright 2013 by Cory Sandone. Used with permission)
